CompletedNCT01010789
Armodafinil for binge-eating disorder
About this title
Read the official source — NCT01010789Medication studyAges 18–65United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- MasonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01010789
- Official title
Show the full official title
Armodafinil in Binge Eating Disorder (BED)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Mason
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Did this study involve medication?
Yes. The study involved medication, including Armodafinil and Matching placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
